SPL-006: An Open-label Phase 1 Trial of the Safety and Efficacy of Daily Subcutaneous SPL-108 Injections When Used in Combination with Paclitaxel in Patients with Platinum-resistant, CD44+, Advanced Ovarian Epithelial Cancer.

Print this page

SPL-006: An Open-label Phase 1 Trial of the Safety and Efficacy of Daily Subcutaneous SPL-108 Injections When Used in Combination with Paclitaxel in Patients with Platinum-resistant, CD44+, Advanced Ovarian Epithelial Cancer.

The objectives of this trial are to:
Primary Objective
h Determine the safety of SPL-108 in combination with paclitaxel
(PTX) under the conditions of the trial.
Secondary Objective
h Document any observed efficacy of daily subcutaneous (SC)
injections of SPL-108 when administered in combination with
PTX in women with CD44+ ovarian cancer whose disease has
progressed or recurred after platinum-based chemotherapy.

Protocol Number: 051607
Phase: Phase I
Applicable Disease Sites: Ovary
Drugs Involved: SPL-108
PACLITAXEL
Principal Investigator: Lorna Rodriguez
Research Nurse: Yasmeen Beckett
Scope: Local
Therapies Involved: Chemotherapy multiple agents systemic
Participating Institutions: Rutgers Cancer Institute of New Jersey

For further information on this clinical trial, please contact us at 732-235-8675 or cinjclinicaltrials@cinj.rutgers.edu.

 

precision medicine at Rutgers Cancer Institute

 

 

 

Donate Now

 

 

 


 

 

 

 

Proud member of
Big Ten Cancer Research Consortium

 

 

Rutgers Health